Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by high metastatic potential, poor prognosis, and limited effective therapeutic options. In this study, we investigated the molecular mechanisms underlying the anticancer effects of the nucleolin (NCL)-targeting DNA aptamer AS1411 using label-free quantitative proteomic profiling. AS1411 treatment significantly reduced TNBC cell viability and migration. To uncover the underlying mechanisms, we performed